Group A Streptococcus Liposomal Vaccine
Group Astreptococcus (GAS) diseases take 90% of streptococcal infection. GAS infectionlead to over 111 million prevalent cases of streptococcal pyoderma, and 616million new cases of GAS pharyngitis each year. Serious infections result whenthe organism spreads to contiguous sites or disseminates to deep tissues, whichmay be accompanied by suppurative complications,such as: cellulitis,erysipelas, necrotic fasciitis, sepsis etc. and nonsuppurative complicationssuch as: acute rheumatic fever (ARF), which may further lead to acute heartdisease and post-streptococcal glomerulonephritis (PSGN) etc.
Due to the structure variation of GASpathogenicity-related M protein, thereare nearly 150 serotypes of GAS, but there is no cross immunity among them. This property makes it particularlydifficult to treat and prevent the GAS infections. Thus, a vaccine capable ofpreventing GAS infections from different serotypes becomes a good solution.
Recombinant Staphylococcus Aureusvaccine (E. Coli.)
Staphylococcus aureus is a major pathogenic bacterium that causes hospital infection and community infection. Along with the long-term and widely use of antibiotics, bacteria resistance become moreserious day by day. As a typical case, Methicillinresistant Staphylococcus Aureus,MRSA, since founded in 1961, has become one of the hospital pathogenic bacteria that contribute most to the infections in global ICU, postoperative infection,burns and war injuries.
Adsorbed Tetanus Vaccine
Tetanus vaccine is a detoxificated toxoid. Traditionally, the vaccine is produced by the cultivation of tetanus bacillus, with filtration methodology to collect the toxin, then have formaldehyde detoxification and purification etc.